Opinion|Videos|January 6, 2025
Insights Into Ongoing Investigational Studies in Lung LCNEC
Author(s)Martin Dietrich, MD, PhD, Soo-Ryum Yang, MD
Panelists discuss ongoing lung large cell neuroendocrine carcinoma (LCNEC) trials involving both familiar and novel agents, including phase 2 durvalumab + EP (1L), phase 2 LCNEC-ALPINE atezolizumab + EP (1L), phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific antibody (2L+), and phase 1 LB2102 DLL2-directed CAR T (2L+).
Advertisement
Episodes in this series
- Please briefly describe and provide any thoughts for ongoing lung LCNEC trials, with both familiar and novel agents:
- Phase II durvalumab + EP, 1L
- Phase 2 LCNEC-ALPINE atezolizumab + EP, 1L
- Phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific ab, 2L+
- Phase 1 LB2102 DLL2-directed CAR T, 2L+
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
In a phase 1/2 study, the LSD1 inhibitor bomedemstat reduced spleen volume, improved symptoms, and lowered driver mutation burden in patients with advanced myelofibrosis.
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5